NICE recommends Amryt’s Filsuvez for rare skin disorder
Around 670 people in England with epidermolysis bullosa will benefit from the treatment
Read More
Tag: epidermolysis bullosa
Amryt’s epidermolysis bullosa trial extended
Amryt’s AP101 EASE Phase III trial has been extended to include infants aged 21 days to four years.
Read More
Green light for Amryt’s epidermolysis bullosa study
An Independent Data Monitoring Committee (IDCM) has recommended that Amryt’s pivotal Phase III EASE trial for AP101 – a potential treatment for Epidermolysis Bullosa (EB) – should continue, raising hopes for a new therapy for the condition.
Read More
Amryt in-licenses novel gene therapy platform from UCD
UK biotech Amryt has secured itself access to a novel gene therapy platform that could give rise to a new treatment option for patients with Epidermolysis bullosa (EB), a group of rare inherited skin disorders that cause the skin to become very fragile.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
